showcase.par.54911.image.0.0.1

Human infections with a new avian influenza A (H7N9) virus continue to be reported. Life Technologies’ team is working diligently to gather all relevant information related to the Avian Influenza (H7N9) virus. Below are the listings of the recommended protocols and the relevant products. 

Recommended protocols

Products for Human Surveillance

SuperScript® III Platinum® One-Step qRT-PCR 
Part of the Human Health response to this disease outbreak and are among the solutions recommended by the Centers for Disease Control and Prevention.
Product Packaging Sizes:

  • 11732-020 – 100 reactions per unit (without ROX)
  • 11732-088 – 500 reactions per unit (without ROX)
  • 11745-100 – 100 reactions per unit (with ROX)
  • 11745-500 – 500 reactions per unit (with ROX)

CDC Protocol

AgPath™ OneStep RT-PCR Master Mix *
Part of the Human Health response to this disease outbreak and are among the solutions recommended by several International Disease Control Centers. 
Product Packaging Sizes:

  • AM1005 – 100 reactions per unit
  • 4384724 – 500 reactions per unit
  • 4387391 – 1000 reactions per unit

Download the Protocol for AgPath™
World Health Organization H7N9 Specific Protocol

* For Research Use Only. Not for use in diagnostic procedures. Referenced in WHO protocol only.

 

7500 Fast Dx Real-Time PCR System

  • 96-well, 5-color real-time PCR for in vitro diagnostic use
  • Delivers performance required for high-quality results

CDC Protocol
Learn more >

** Vendors or manufacturers in the CDC protocol are provided as examples of suitable product sources and do not imply endorsement by the Centers for Disease Control and Prevention.

Products for Avian Surveillance

MagMAX™-96 AI/ND Viral RNA Isolation Kit – SKU AM1835

  • Validated by the US National Veterinary Service Laboratories specifically for use in Avian Influenza detection.
  • 480 Samples per Unit.

Download the Protocol

MagMAX™-96 Viral RNA Isolation Kit – SKU AM1836, AMB1836-5

  • Improved Chemistry versus AM1835
  • 50uL & 100uL Sample Size
  • 96 Samples per Unit
  • -5 SKU has 480 Samples per Unit

Download the User Guide

MagMAX™ Pathogen RNA⁄DNA Kit SKU - 4462359

  • Chemistry same as AM1836
  • Up to 300 uL Sample Size
  • 480 Samples per Unit

Download the Protocol

HomeBrew Assays (Screening & SubTyping)

AgPath OneStep RT-PCR Master Mix
Designed for broad Animal Health usage.
Product Packaging Sizes:

  • AM1005 (100 reactions)
  • 4384724 (500 reactions)
  • 4387391 (1000 reactions)

Download the Protocol for AgPath™

Path-ID™ Multiplex One-Step RT-PCR Kit
Designed for use with Complex and Multiplexed Assays.
Product Packaging Sizes:

  • 4442135 (100 reactions)
  • 4442136 (500 reactions)
  • 4442137 (1000 reactions)

Download the Protocol for Path-ID™
World Health Organization H7N9 Specific Protocol

Screening Tools

VetMax® Gold SIV Detection Kit* - SKU 4415200
Our most robust and sensitive Influenza A product. Bio-Informatics analysis of publically available sequences suggests an excellent match with currently circulating H7N9 strains in China.
Product Insert Sheet

TaqMan® Avian Influenza Virus (AIV-M) Reagents – SKU 4405543
Based on the design recommended by the US National Veterinary Service Laboratories for screening for Avian Influenza and is widely utilized around the world. This product contains reagents ONLY and should be combined with TaqMan® Avian Influenza Virus (AIV-M) and Xeno™ RNA Controls SKU 4405544.
Product Insert Sheet for the Reagents
Product Insert Sheet for the Controls

VLA TaqMan® Influenza A Detection Kit * – SKU 4398276
Co-Developed and Validated with the United Kingdom Animal Health and Veterinary Laboratories Agency.
Lyophilized format.
Additional product information >

LSI™ VetMAX™ Influenza A* – SKU INFAP200950
Kit format – only requires sample prep for complete workflow.
50 Reactions per unit.
Additional product information >

Sub Typing Tools

LSI™ VetMAX™ Avian influenza H7 Typing Real-Time PCR Kit *– SKU AIH7P50
We are currently awaiting Field Reports regarding its efficacy with the currently circulating H7N9 strains in China.
50 Reactions per unit.
Additional product information >

* This product is not available in all geographic regions. Contact your Life Technologies representative for more information.

7500 Real-Time PCR System

  • 5-color dye flexibility in a trusted 96-well format

Learn more >

7500 Fast Real-Time PCR System

  • 96-well-format high-speed thermal cycling, delivering high quality results in less than 30 minutes

Learn more >

7500 Fast Dx Real-Time PCR System

  • 96-well, 5-color real-time PCR for in vitro diagnostic use
  • Delivers performance required for high-quality results

Learn more >

QuantStudio™ 12K Flex Real-Time PCR System

  • Maximum throughput
  • Supports OpenArray® plate, TaqMan® Array Card, 384-well, Fast 96-well, and 96-well formats.
  • Start a 12,000 data point experiment typically in 20 minutes or less.

Learn more >

QuantStudio™ Dx Real-Time PCR System

  • Real-time PCR for in vitro diagnostic use
  • 96-well fast format in US
  • TaqMan® Array Card, 96-well fast and standard, and 384-well formats in Europe
  • Diagnostic workflow with reagent and sample tracking, maintenance and calibration reports, and LIS/LIMS connectivity

Learn more >

Consumables

Instruments

The CDC’s Influenza A/H7 (Eurasian Lineage) Real-Time RT-PCR Diagnostic Assay has received Emergency Use Authorization for detection in patient specimens of the novel influenza A (H7/N9) virus and not for the diagnosis of any other viruses or pathogens. The CDC A/H7 Assay has not been FDA cleared or approved, nor has FDA determined, as permitted under section 564(m) of the Act, that this test may be performed in settings with certificates of waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a. The CDC A/H7 Assay is only authorized for the duration of the declaration of emergency under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C § 360bbb-#(b)(1), unless the authorization is revoked sooner and the declaration of emergency will terminate when the HHS Secretary determines that the circumstances of a significant potential for a public health emergency have ceased to exist or when there is a change in the approval status of the CDC A/H7 Assay such that the authorization of emergency use is no longer needed, whichever occurs earlier.